QuickView for 4 methyl- n-( 3-( 4- methylimidazol- 1- yl)- 5-( trifluoromethyl) phenyl)- 3-(( 4- pyridin- 3- ylpyrimidin- 2- yl) amino) benzamide

1. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
3. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
4. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
5. L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens

There were no matches for 4 methyl- n-( 3-( 4- methylimidazol- 1- yl)- 5-( trifluoromethyl) phenyl)- 3-(( 4- pyridin- 3- ylpyrimidin- 2- yl) amino) benzamide

There were no clinical trials for 4 methyl- n-( 3-( 4- methylimidazol- 1- yl)- 5-( trifluoromethyl) phenyl)- 3-(( 4- pyridin- 3- ylpyrimidin- 2- yl) amino) benzamide